



11th & 12th January 2016

PARIS - Palais des Congrès

**International Conference on the Management
of Patients with Viral Hepatitis**

Organised by Pr Patrick Marcellin

Organising Committee

Emilie Estrabaud, Michelle Martinot-Peignoux, Monelle Muntlak
Hôpital Beaujon, APHP - INSERM CRI - Université Paris-Diderot

Scientific Committee

Marc Bourlière, Massimo Colombo, Rafael Esteban,
Graham Foster, Michael Fried, Michael Manns

www.aphc.info



Follow us on Twitter: @PHC_off #PHC2016



Dear Colleagues,

We are pleased to welcome you at the 9th Paris Hepatitis Conference (PHC).

As usual, the meeting will provide state of the art information on the management of patients with hepatitis B and hepatitis C by leading edge international experts who will present the most recent data and their opinion on the clinical applications.

Thanks to the outstanding progress made in the treatment of hepatitis C with the new combinations of DAAs, 95% of patients with HCV can now potentially be cured including formerly « difficult to treat » patients (cirrhotics, coinfection with HIV, transplantation...). These combinations are well tolerated and very effective in all genotypes with shorter treatment (almost 100% SVR after 12 weeks of treatment and a significant portion of the population responding after just 8 weeks). Indeed, these advances raise the issue of how to facilitate access to treatment in more patients with the realistic objective of eradicating hepatitis C.

Eradication of HCV is now a dream shared by experts all over the world. To reach this goal a joint strategy is necessary including different regions and countries. To further our investigation in this direction we decided to create an international scientific committee for the PHC 2016. I would like to warmly thank my colleagues Marc Bourlière (France), Massimo Colombo (Italy), Rafael Esteban (Spain), Graham Foster (UK), Michael Fried (USA), and Michael Manns (Germany) who have accepted to participate in this committee.

As discussed during the 8th PHC, recent treatments are not yet available in most countries with large populations of HCV patients. First or second-generation of DAAs therapies have just been introduced in many countries. Therefore, optimal strategies that take into account the severity of the liver disease must be defined in relation to available resources and drugs.

The PHC 2016 will also spend a full day addressing important issues related to hepatitis B. We will discuss the long-term efficacy and tolerance in patients receiving the most potent available antivirals. Recent studies with up to 8 years of treatment report favourable outcomes with the regression of fibrosis and a decrease in the incidence of HCC in treated patients without viral resistance. We will also address the role of quantification of HBsAg which seems to be a new tool to assess the severity of the disease and the response to therapy. Finally the optimal management of difficult populations will be extensively discussed: co-infections, cirrhosis...

As in previous PHCs, interactive discussions and specific lunch workshops have been organised to review the management of real life patients. Indeed, the ultimate goal of the PHC 2016 is to review the most current knowledge and discuss their therapeutic applications with the most experienced experts to provide optimal therapy and the best chance of cure to as many patients as possible, worldwide.

We wish you a pleasant meeting,

Professor Patrick Marcellin
President of the 9th Paris Hepatitis Conference

HEPATITIS C

08.30 Introduction: Treatment of hepatitis C: Access to eradication!

Patrick Marcellin (France)

08.40 - 09.00 State of the art lecture

Chairman: Tarik Asselah (France)

■ The influence of therapy on the burden of hepatitis C

Michael Fried (USA)

09.00 - 10.00 Who to treat?

Chairmen: Antonio Craxi (Italy), Stanislas Pol (France)

09.00 ■ Why do I treat my patients with mild hepatitis?

Antonio Craxi (Italy)

09:15 ■ Why don't I treat my patients with mild hepatitis?

Christophe Hézode (France)

09.30 ■ Is the benefit to treat patients with cirrhosis proven?

Savino Bruno (Italy)

09:45 ■ Round table discussion

☕ 10.00 - 10.20 Coffee break

10.20 - 11.05 How to optimize therapy?

Chairmen: Marc Bourlière (France), Jake Liang (USA)

10.20 ■ Is it useful to detect resistance associated variants?

Stefan Zeuzem (Germany)

10.35 ■ Individual optimization of therapy (shorten therapy)

Graham Foster (UK)

10.50 ■ Round table discussion

11.05 - 12.30 How to improve access to therapy? Around the World table

NORTH & WEST

Chairman: Massimo Colombo (Italy)

Speakers: Nezam Afdhal (USA), Victor de Ledinghen (France), Rafael Esteban (Spain), Graham Foster (UK), Michael Manns (Germany)

SOUTH & EAST

Chairmen: Robert Flisiak (Poland), Adrian Gadano (Argentina)

Speakers: Raymundo Parana (Brazil), Vasily Isakov (Russia), Mihai Voiculescu (Romania)

12.30 - 14.30 Lunch Workshops

14.30 - 15.35 Special populations

Chairpersons: Maria Buti (Spain), François Durand (France)

14:30 ■ Patients with chronic kidney diseases

Stanislas Pol (France)

14:45 ■ DAAs and transplanted patients

Didier Samuel (France)

15:00 ■ HIV-HCV co-infected patients

Mark Sulkowski (USA)

15:15 ■ Round table discussion

☕ 15:35 - 16:05 Coffee break

16.05 - 16.55 New therapeutic strategies

Chairmen: Michael Manns (Germany), Marc Bourlière (France)

16.05 ■ How to improve the therapeutic strategies ?

Tarik Asselah (France)

16.20 ■ How to provide the best treat with what is available?

David Nelson (USA)

16.35 ■ Round table discussion

16.55 - 17.40 How to optimize the strategy against HCV?

Chairmen: Peter Ferenci (Austria), Eugene Schiff (USA)

16.55 ■ Universal screening?

Mitchell Shiffman (USA)

17.10 ■ Follow-up of patients with SVR

Lawrence Serfaty (France)

17:25 ■ Round table discussion

17.40 - 17.50 Take home messages

Massimo Colombo (Italy)

17.50 - 18.00 Conclusion

Patrick Marcellin (France)

19.30 Congress dinner

PROGRAMME OF THE LUNCH WORKSHOPS

For people not registered to the lunch workshops, regular lunches are organised on Level 4

11th January from 12:30 to 14:30

Room 252B

Future therapies for HBV and HDV: what can we expect?

Chairs: Michael Manns (Germany), Jake Liang (USA)

Speakers: Adrian Gadano (Argentina),

Massimo Levrero (Italy)

Room 242A

First line therapy of hepatitis B: interferon or analogues?

Chairs: Graham Foster (UK), Jia-Horng Kao (Taiwan)

Speakers: Georgios Papatheodoridis (Greece),

Philippe Mathurin (France)

Room 242B

Clinical applications of HBsAg quantification

Chairs: Philippe Halfon (France), Ji Dong Jia (China)

Speakers: Antonio Craxi (Italy),

Rami Moucari (United Arab Emirates)

Room 253

Staging of steatosis and fibrosis: liver biopsy or indirect markers?

Chairs: Pierre Bedossa (France),

Victor De Ledinghen (France)

Speakers: Laurent Castera (France),

Ana Carolina Cardoso (Brasil)

Room 251

Treatment of HCV cirrhosis and transplanted patients: when and how?

Chairs: Didier Samuel (France),

Dominique Valla (France)

Speakers : François Durand (France),

Georges-Philippe Pageaux (France)

Room 241

HIV-HCV coinfections

Chairs: Mark Sulkowski (USA), Stanislas Pol (France)

Speakers: Dominique Salmon (France),

Yazdan Yazdanpanah (France)

Room 243

Traitement HBV : Interféron ou analogues? (French speaking lunch workshop)

Chairs: Christian Trepo (France),

Jean-Pierre Zarski (France)

Speakers : Philippe Sogni (France), Nabil Debzi (Algeria)

Room 252A

HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)

Chairs: Denis Ouzan (France),

Jean-François Cadranel (France)

Speakers: Adriana Popescu (Romania),

Albert Tran (France)

12th January from 12:15 to 14:15

Room 253

Can we expect eradication in HCV G4?

Chairman: Gamal Esmat (Egypt)

Speakers: Tarik Asselah (France), Imam Waked (Egypt)

Room 251

Are DAAs therapies associated with HCV eradication?

Chairs: Lawrence Serfaty (France),

Mitchell Shiffman (USA),

Speakers: Vincent Di Martino (France),

Emilie Estrabaud (France)

Room 243

How to manage relapsers and non-responders to PEG-IFN + RBV therapy?

Chairs: Peter Ferenci (Austria), Adrian Di Bisceglie (USA)

Speakers: Konstantin Zhdanov (Russia),

Andrzej Horban (Poland)

Room 242A

How to optimize treatment in G3 patients?

Chairs: Michael Fried (USA), Marc Bourlière (France)

Speakers: Massimo Colombo (Italy),

Jérôme Gournay (France)

Room 252B

Need to assess HCV resistance profile before the initiation of DAAs therapy?

Chairman: Fabien Zoulim (France)

Speakers: Robert Flisiak (Poland),

Christophe Hézode (France)

Room 242B

Management and treatment of NASH

Chairs: Vlad Ratziu (France),

Antonello Pietrangelo (Italy)

Speakers: Raluca Pais (France),

Petr Urbánek (Czech Republic)

Room 252A

Traitements des patients atteints de cirrhose (French speaking lunch workshop)

Chairs: Mihai Voiculescu (Romania),

Jean-Pierre Bronowicki (France),

Speakers : Claire Francoz (France),

Mustapha Benazzouz (Morocco)

Room 241

HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)

Chairs: Daniel Dhumeaux (France),

Philippe Mathurin (France)

Speakers: Najet Bel Hadj Brik (Tunisia),

Vincent Leroy (France)

HEPATITIS B

08.30 Introduction: Hepatitis B, the come back? *Patrick Marcellin (France)*

08.40 - 10.00 What's new in hepatitis B?

Chairmen: Laurent Castera (France), Fabien Zoulim (France)

08.40 ■ Clinical relevance of HBV cccDNA *Fabien Zoulim (France)*

08.55 ■ Virological markers for the management of patients *Michelle Martinot-Peignoux (France)*

09.10 ■ New therapeutic perspectives? *Jia-Horng Kao (Taiwan)*

09.30 ■ Round table discussion

☕ 10.00 - 10.30 Coffee break

10.30 - 11.45 Optimal therapy of chronic hepatitis B

Chairmen: Adrian Gadano (Argentina), Ji Dong Jia (China)

10.30 ■ Do I treat my immunotolerant patients? *Georgios Papatheodoridis (Greece)*

10.45 ■ Prognosis and management of inactive carriers *Pietro Lampertico (Italy)*

11.00 ■ Which pregnant women to treat? *Ji Dong Jia (China)*

11.15 ■ Round table discussion

11.45 - 12.15 State of the art lecture

Chairman: Marc Bourlière (France)

■ Hepatitis E: the neglected one *Jean-Marie Péron (France)*

12.15 - 14.15 Lunch Workshops

14.15 - 14.45 State of the art lecture and award

Chairman: Patrick Marcellin (France)

■ The adventure of Delta *Mario Rizzetto (Italy)*

14.45 - 16.00 End-stage liver disease is a multifaceted condition

Chairmen: Adrian Di Bisceglie (USA), Richard Moreau (France)

14.45 ■ Management of uninfected and infected ascites in cirrhosis *Pere Gines (Spain)*

15.00 ■ Iron and the liver *Antonello Pietrangelo (Italy)*

15.15 ■ Treatment of hepatocellular carcinoma: beyond international guidelines *Massimo Colombo (Italy)*

15.30 ■ Round table discussion

16.00 Take home messages

Marc Bourlière (France)

16.10 Conclusion

Patrick Marcellin (France)

16.20 Closing session

GENERAL INFORMATION

CONFERENCE DATES AND VENUE

From Monday 11th to Tuesday 12th January 2016
At the “Palais des Congrès”
2, place de la Porte Maillot
75017 Paris – France

Metro and RER station:
“Porte Maillot”

CONFERENCE REGISTRATION DESK

11th & 12th January, from 7:30 am.
Welcome desks are organised on level 2 of the Palais de Congrès in Foyer Bleu next to the Amphitheatre Bleu. You will be able to retrieve your access badge, congress bag and proceedings.

CONGRESS OFFICE

Quadrature Santé / PHC 2016
43 rue des Tilleuls
92100 Boulogne-Billancourt
Phone: +33 1 41 10 46 65
Fax: +33 1 41 10 46 69
Contact: contact@phc-congress.com
www.aphc.info

CONGRESS HOTELS

Hyatt Regency Paris Étoile
3 place du Général Koenig
75017 Paris
Tel : +33 (0) 1 40 68 12 34

Méridien Etoile Hotel
81 boulevard Gouvion St-Cyr
75 017 Paris
Tel: +33 (0)1 40 68 34 34

CONGRESS DINNER

Monday 11th January at the
Pré Catelan
Bois de Boulogne,
Route de Suresnes, 75016 Paris
Buses will leave from the Palais des
Congrès from 7:00 p.m.
Dress code : cocktail attire

CME CONTINUOUS MEDICAL EDUCATION ACCREDITATION

The “APHC” is accredited by the European
Accreditation Council for Continuing
Medical Education (EACCME) to provide
the following CME activity for medical
specialists.
The 9th Paris Hepatitis Conference is
designated for a maximum of (or “for up to”)
11 European CME credits (ECMEC).

LIVER INTERNATIONAL

The PHC Liver International Supplement is
available online at the following address:
<http://blackwellpublishing.com>

LUNCHES

2 types of lunches are organised
each day:

- *Lunch Workshops* (Level 2).
The number of seats is limited.
- *Regular lunches* are organised in Salon
Arc en Ciel (Level 4).

METRO and RER

The metro station (line 1) and RER station
(line C) are located on level -1 of the
Palais des Congrès: Porte Maillot station.
The Conference will be held in
Amphitheatre Bleu on level 2.

OFFICIAL LANGUAGE

The official language
of the conference is English.

